Pharmaceutical Technology10 天
YH-013 by Eucure (Beijing) Biopharma for Metastatic Colorectal Cancer: Likelihood of Approval
Biopharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication ...
Pharmaceutical Technology10 天
YH-013 by Eucure (Beijing) Biopharma for Metastatic Pancreatic Cancer: Likelihood of Approval
Biopharma and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData, Phase I drugs for Metastatic Pancreatic Cancer have an 88% phase transition success rate (PTSR) indication ...